Paper28314976
Enzyme replacement therapy and beyond-in memoriam Roscoe O. Brady, M.D. (1923-2016).
Ries M. J Inherit Metab Dis, 2017. Cited by 38 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Enzyme replacement therapy and beyond-in memoriam Roscoe O. Brady, M.D. (1923-2016). Papers, record 28314976. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28314976
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Lysosomal Storage Diseases | Major topic |
| Animals | |
| Biomarkers | |
| Clinical Trials as Topic | |
| Enzyme Replacement Therapy | |
| Genetic Therapy | |
| Humans | |
| Lysosomes | |
| Molecular Chaperones |
Source PubMed
References90
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21417264 | Strategies for Neoglycan conjugation to human acid α-glucosidase. | Bioconjug Chem | 2011 | https://conductscience.org/library/papers/21417264 | PubMed |
| 2 | 4236721 | Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. | Science | 1968 | https://conductscience.org/library/papers/4236721 | PubMed |
| 3 | 22167193 | Ex vivo and in vivo effects of isofagomine on acid β-glucosidase variants and substrate levels in Gaucher disease. | J Biol Chem | 2012 | https://conductscience.org/library/papers/22167193 | PubMed |
| 4 | 22279584 | CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder. | PLoS One | 2012 | https://conductscience.org/library/papers/22279584 | PubMed |
| 5 | 19750228 | Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. | PLoS One | 2009 | https://conductscience.org/library/papers/19750228 | PubMed |
| 6 | 15669681 | Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease. | J Inherit Metab Dis | 2004 | https://conductscience.org/library/papers/15669681 | PubMed |
| 7 | 18713755 | Reversal of peripheral and central neural storage and ataxia after recombinant enzyme replacement therapy in alpha-mannosidosis mice. | Hum Mol Genet | 2008 | https://conductscience.org/library/papers/18713755 | PubMed |
| 8 | 12803917 | Biosynthesis and degradation of mammalian glycosphingolipids. | Philos Trans R Soc Lond B Biol Sci | 2003 | https://conductscience.org/library/papers/12803917 | PubMed |
| 9 | 10801168 | Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. | Lancet | 2000 | https://conductscience.org/library/papers/10801168 | PubMed |
| 10 | 19775699 | Twice-daily cysteamine bitartrate therapy for children with cystinosis. | J Pediatr | 2010 | https://conductscience.org/library/papers/19775699 | PubMed |
| 11 | 25688781 | Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial. | JAMA | 2015 | https://conductscience.org/library/papers/25688781 | PubMed |
| 12 | 23194248 | Gene therapy for mucopolysaccharidosis type VI is effective in cats without pre-existing immunity to AAV8. | Hum Gene Ther | 2013 | https://conductscience.org/library/papers/23194248 | PubMed |
| 13 | 21496291 | Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders. | Orphanet J Rare Dis | 2011 | https://conductscience.org/library/papers/21496291 | PubMed |
| 14 | 7985893 | Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. | Ann Intern Med | 1995 | https://conductscience.org/library/papers/7985893 | PubMed |
| 15 | 15126990 | Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). | J Pediatr | 2004 | https://conductscience.org/library/papers/15126990 | PubMed |
| 16 | 4236091 | The defect in Hurler's and Hunter's syndromes: faulty degradation of mucopolysaccharide. | Proc Natl Acad Sci U S A | 1968 | https://conductscience.org/library/papers/4236091 | PubMed |
| 17 | 9883849 | Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. | Nat Med | 1999 | https://conductscience.org/library/papers/9883849 | PubMed |
| 18 | 19067373 | Randomized, controlled trial of miglustat in Gaucher's disease type 3. | Ann Neurol | 2008 | https://conductscience.org/library/papers/19067373 | PubMed |
| 19 | 11703994 | Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy. | Am J Cardiol | 2001 | https://conductscience.org/library/papers/11703994 | PubMed |
| 20 | 11439963 | Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. | N Engl J Med | 2001 | https://conductscience.org/library/papers/11439963 | PubMed |
Cited by23
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 38 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40710901 | Advances in Diagnosis, Pathological Mechanisms, Clinical Impact, and Future Therapeutic Perspectives in Tay-Sachs Disease. | Neurol Int | 2025 | https://conductscience.org/library/papers/40710901 | PubMed |
| 39105852 | The role of ceranib-2 and its nanoform on the decrease of telomerase levels in human non-small cell cancer. | Mol Biol Rep | 2024 | https://conductscience.org/library/papers/39105852 | PubMed |
| 38738088 | Current Concepts in the Management of Sanfilippo Syndrome (MPS III): A Narrative Review. | Cureus | 2024 | https://conductscience.org/library/papers/38738088 | PubMed |
| 38664313 | Advances in Immune Tolerance Induction in Enzyme Replacement Therapy. | Paediatr Drugs | 2024 | https://conductscience.org/library/papers/38664313 | PubMed |
| 37654562 | Precocious puberty in patients with Pompe disease. | Front Endocrinol (Lausanne) | 2023 | https://conductscience.org/library/papers/37654562 | PubMed |
| 36566487 | Modifying enzyme replacement therapy - A perspective. | J Cell Mol Med | 2023 | https://conductscience.org/library/papers/36566487 | PubMed |
| 36534309 | Recent topics and advanced therapies in chronic granulomatous disease. | Hum Cell | 2023 | https://conductscience.org/library/papers/36534309 | PubMed |
| 36412587 | A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease. | Int J Neonatal Screen | 2022 | https://conductscience.org/library/papers/36412587 | PubMed |
| 35865957 | Therapeutic Strategies For Tay-Sachs Disease. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35865957 | PubMed |
| 35036673 | Lysosome-Targeting Strategy Using Polypeptides and Chimeric Molecules. | ACS Omega | 2022 | https://conductscience.org/library/papers/35036673 | PubMed |
| 34835710 | Tween® Preserves Enzyme Activity and Stability in PLGA Nanoparticles. | Nanomaterials (Basel) | 2021 | https://conductscience.org/library/papers/34835710 | PubMed |
| 34199011 | Nanofibrous Formulation of Cyclodextrin Stabilized Lipases for Efficient Pancreatin Replacement Therapies. | Pharmaceutics | 2021 | https://conductscience.org/library/papers/34199011 | PubMed |
| 33766102 | New paradigms for the treatment of lysosomal storage diseases: targeting the endocannabinoid system as a therapeutic strategy. | Orphanet J Rare Dis | 2021 | https://conductscience.org/library/papers/33766102 | PubMed |
| 33711910 | Current and emerging pharmacotherapy for Gaucher disease in pediatric populations. | Expert Opin Pharmacother | 2021 | https://conductscience.org/library/papers/33711910 | PubMed |
| 33417459 | Relevance of Electrostatics for the Interaction of Tyrosine Hydroxylase with Porous Silicon Nanoparticles. | Mol Pharm | 2021 | https://conductscience.org/library/papers/33417459 | PubMed |
| 32267884 | FDA orphan drug designations for lysosomal storage disorders - a cross-sectional analysis. | PLoS One | 2020 | https://conductscience.org/library/papers/32267884 | PubMed |
| 31209777 | Therapeutic Options for Mucopolysaccharidoses: Current and Emerging Treatments. | Drugs | 2019 | https://conductscience.org/library/papers/31209777 | PubMed |
| 30442189 | Enzyme replacement therapy: efficacy and limitations. | Ital J Pediatr | 2018 | https://conductscience.org/library/papers/30442189 | PubMed |
| 30318473 | Coexpression of novel furin-resistant LPL variants with lipase maturation factor 1 enhances LPL secretion and activity. | J Lipid Res | 2018 | https://conductscience.org/library/papers/30318473 | PubMed |
| 30004274 | Digital microfluidics comes of age: high-throughput screening to bedside diagnostic testing for genetic disorders in newborns. | Expert Rev Mol Diagn | 2018 | https://conductscience.org/library/papers/30004274 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28314976
GET https://conductscience.org/api/papers/v1/28314976/references?page=2